Results 161 to 170 of about 559,417 (315)

Evidence-based medicine: challenging the orthodoxy [PDF]

, 1998
David G. Grahame‐Smith
openalex   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review. [PDF]

Ann Med
Untaaveesup S, Srichana P, Techataweewan G, Pongphaew C, Dendumrongsup W, Ponvilawan B, Nampipat N, Limwongse C.   +7 more
europepmc   +1 more source

Evidence-based medicine and the practicing clinician

, 1999
Finlay A. McAlister, Ian D. Graham, Gerald W. Karr, Andreas Laupacis   +3 more
openalex   +2 more sources

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma. [PDF]

Nat Commun
Shinozaki T, Togasaki K, Hamamoto J, Mitsuishi A, Fukushima T, Sugihara K, Ebisudani T, Okada M, Saito A, Shigematsu L, Takaoka H, Ito F, Ohgino K, Ishioka K, Watanabe K, Hishima T, Kurebayashi Y, Emoto K, Terai H, Ikemura S, Kawada I, Asakura K, Hishida T, Asamura H, Ohta Y, Takahashi S, Oda M, Saito M, Matano M, Soejima K, Fujii M, Fukunaga K, Yasuda H, Sato T.   +33 more
europepmc   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Metabolic Reprogramming of Urothelial Carcinoma-A Theragnostic Target for Betulinic Acid. [PDF]

Int J Mol Sci
Ganguly A, Halder A, Healy K, Daugherty S, Kimura S, Banerjee R, Beckel JM, Tyagi P.   +7 more
europepmc   +1 more source

Clinical observation on treatment of postcardiotomic complications with Chinese herbal medicine based on syndrome differentiation in 58 patients with angiocardiopathy [PDF]

, 1999
Lihong Ma, Zeng-mian Jiao, Ruihua Zhang
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source